Stockscreener 앱 받기
1.58
6.04%
0.09
시장 영업 전:
1.47
-0.11
-6.96%
전일 마감가:
$1.49
열려 있는:
$1.52
하루 거래량:
226.89K
Relative Volume:
0.55
시가총액:
$166.47M
수익:
$17.91M
순이익/손실:
$-47.66M
주가수익비율:
-3.4756
EPS:
-0.4546
순현금흐름:
$-62.63M
1주 성능:
-8.14%
1개월 성능:
+2.60%
6개월 성능:
-23.67%
1년 성능:
-1.86%
1일 변동 폭
$1.49
$1.58
1주일 범위
$1.45
$1.69
52주 변동 폭
$1.07
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.58 | 166.47M | 17.91M | -47.66M | -62.63M | -0.4546 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 재개 | Oppenheimer | Outperform |
| 2025-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-04-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-01-10 | 개시 | Oppenheimer | Outperform |
| 2024-10-29 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-02-11 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-02-01 | 개시 | Raymond James | Strong Buy |
| 2021-05-03 | 개시 | Stifel | Buy |
| 2021-03-25 | 재확인 | Citigroup | Buy |
| 2020-11-03 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-03-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-12-19 | 개시 | RBC Capital Mkts | Outperform |
| 2018-11-15 | 개시 | Citigroup | Buy |
| 2018-09-19 | 개시 | Evercore ISI | Outperform |
| 2017-09-26 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-06-20 | 개시 | Chardan Capital Markets | Neutral |
| 2014-10-15 | 개시 | Deutsche Bank | Buy |
| 2014-10-13 | 개시 | H.C. Wainwright | Buy |
모두보기
Proqr Therapeutics N V 주식(PRQR)의 최신 뉴스
Price Action: Is ProQR Therapeutics NV attractive for institutional investors2026 Pullback Review & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts - Yahoo Finance UK
ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline - TipRanks
ProQR (PRQR) schedules April 8 virtual event on Axiomer RNA pipeline - Stock Titan
Ahead of AX-0810 data, ProQR plans April 8 pipeline webcast - Stock Titan
If You Invested $1,000 in Proqr Therapeuti (PRQR) - Stock Titan
Evercore ISI Group Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Outperform Recommendation - MSN
Insider Sell: Can ProQR Therapeutics NV weather a recessionPortfolio Gains Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Research Analysts Set Expectations for PRQR Q2 Earnings - Defense World
ProQR (NASDAQ: PRQR) director details substantial share and long-dated option holdings - Stock Titan
ProQR (PRQR) CSO details sizeable option grants and share stake - Stock Titan
Director Maier details ProQR (PRQR) share option grants and vesting - Stock Titan
ProQR (PRQR) director Alison Lawton details multiple option grants - Stock Titan
ProQR (PRQR) CFO discloses 1,000,000-share option position in Form 3 - Stock Titan
Theresa Heggie (PRQR) details option and share holdings in Form 3 - Stock Titan
ProQR Therapeutics N.V. (PRQR) director files Form 3 for options - Stock Titan
ProQR (PRQR) CEO Daniel de Boer details long-dated option grants - Stock Titan
ProQR Therapeutics (PRQR) director reports five long-dated option grants - Stock Titan
ProQR Therapeutics (PRQR) director discloses share and option holdings - Stock Titan
Q2 Earnings Estimate for PRQR Issued By HC Wainwright - MarketBeat
Brokers Issue Forecasts for PRQR Q1 Earnings - MarketBeat
Aug Sentiment: Whats the RSI of ProQR Therapeutics NV stock2026 Highlights & Low Risk Profit Maximizing Plans - baoquankhu1.vn
ProQR Therapeutics N.V.Ordinary Shares (NQ: PRQR - The Chronicle-Journal
Recap Report: Is ProQR Therapeutics NV a strong candidate for buy and hold2026 Volume Leaders & AI Optimized Trade Strategies - baoquankhu1.vn
Breakout Zone: Is ProQR Therapeutics NV attractive for institutional investors2026 Opening Moves & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
ProQR Therapeutics NV earnings beat by €0.02, revenue topped estimates By Investing.com - Investing.com Australia
ProQR Therapeutics (NASDAQ:PRQR) Raised to Hold at Wall Street Zen - MarketBeat
ProQR Therapeutics NV earnings beat by €0.02, revenue topped estimates - Investing.com Nigeria
ProQR Therapeutics (NASDAQ:PRQR) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Citizens reiterates ProQR Therapeutics stock rating on RNA editing platform potential - Investing.com
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
PRQR SEC FilingsProqr Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Coverage Initiated at Oppenheimer - MarketBeat
ProQR Therapeutics Q4 2025 Financial Results: Loss of $9.1MNews and Statistics - IndexBox
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
ProQR: Q4 Earnings Snapshot - marketscreener.com
ProQR Therapeutics NV reports results for the quarter ended December 31Earnings Summary - TradingView
ProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027 - TipRanks
ProQR (PRQR) Advances Clinical Trials Amid Reduced Cash Holdings - GuruFocus
ProQR Therapeutics (NASDAQ: PRQR) details 2025 loss, cash runway and RNA editing focus - Stock Titan
ProQR Announces Year End 2025 Operating and Financial Results - weeklyvoice.com
ProQR (Nasdaq: PRQR) widens 2025 loss as R&D spending rises - Stock Titan
ProQR: Fourth Quarter Financial Overview - Bitget
Analysts Set ProQR Therapeutics Price Target at $7.14 - National Today
ProQR Therapeutics NV expected to post a loss of 10 cents a shareEarnings Preview - TradingView
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Quarterly Risk: Can ProQR Therapeutics NV weather a recession2025 Big Picture & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Weekly Trades: Is ProQR Therapeutics NV backed by strong institutional buyingJuly 2025 Pullbacks & Verified Momentum Stock Alerts - baoquankhu1.vn
Highs Report: Is ProQR Therapeutics NV a strong candidate for buy and holdMarket Growth Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
Portfolio Shifts: Can ProQR Therapeutics NV benefit from deglobalization2025 Market Sentiment & AI Forecasted Stock Moves - baoquankhu1.vn
Is ProQR Therapeutics NV backed by strong institutional buyingWeekly Trend Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Proqr Therapeutics N V (PRQR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):